Physician profile
Halimo A Abdi
NPI 1053041491
$1,299.34
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $149 · 2023: $1,151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,139 · Education: $11.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,138.93 |
| Education | $11.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $301.09 | 2022-2023 | Mounjaro, Humulin, Lyumjev |
| Dexcom, INC. | $197.79 | 2023 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $151.16 | 2023 | Ozempic, Rybelsus, Wegovy |
| Esperion Therapeutics, INC. | $128.53 | 2022-2023 | Nexletol |
| Antares Pharma, INC. | $116.54 | 2023 | Tlando, Xyosted, Nocdurna |
| Insulet Corporation | $69.48 | 2023 | Omnipod |
| Amneal Pharmaceuticals LLC | $64.58 | 2023 | Unithroid |
| Currax Pharmaceuticals LLC | $54.80 | 2022-2023 | Contrave, Nexlizet, Nexletol |
| Idorsia Pharmaceuticals US INC | $46.94 | 2023 | Quviviq |
| Corcept Therapeutics | $45.11 | 2023 | Korlym |
| Sanofi-Aventis U.S. LLC | $35.61 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.45 | 2023 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.82 | 2023 | Cycloset |
| Abbvie INC. | $16.94 | 2022 | |
| Embecta Corp. | $16.50 | 2023 | Bd Nano 2nd Gen Pen Needle |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Halimo Abdi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.